List of key preventive measures
This toolkit aims to support infection prevention in schools, with a focus on gastrointestinal diseases, by assisting EU/EEA countries in their communication initiatives for disease prevention in school settings.
- Escherichia coli infection
- Food- and waterborne diseases
- Gastrointestinal disease
- Health communication
- Hepatitis A
- Hepatitis E
- Norovirus infection
- Verotoxigenic Escherichia coli infection
Poster with information for travellers
It is important to protect yourself from mosquito bites when staying in the affected areas in order to prevent becoming infected with the virus. How can travelers prevent mosquito bites?
Prevention and control measures for Rift Valley fever
Vaccination of ruminants is the favoured method of preventing human disease. The inactivated RVF vaccine provides a lower level of protection. Other measures include a ban on slaughtering ruminants and avoiding mosquito bites.
Personal protective measures (non-pharmaceutical) for reducing the risk of acquiring or transmitting human influenza
In the absence of a specific vaccine, there are a number of personal measures that people may take to reduce their risk of acquiring influenza. Influenza is a viral infection that spreads from person to person principally when people cough or sneeze, or by direct or indirect contact with respiratory secretions from infectious persons that are on their hands or on surfaces. The following recommendations are based in part on evidence from studies and in part on judgement based on public health experience.
Prevention and control measures for Alkhurma haemorrhagic fever
Prevention and control of Alkhumra infection is achieved by avoiding or minimising the exposure to infected ticks, to the blood of animals during slaughtering activities and by avoiding consumption of non-pasteurized milk.
Treatment and vaccines for Ebola virus disease
In the absence of a licensed vaccine to protect against Ebola virus disease (EVD) or a specific drug for treatment of infected patients in the large Ebola virus outbreak that started in December 2013 in Guinea, and subsequently spread to Liberia and Sierra Leone, potential new Ebola vaccines and therapies were reviewed by the World Health Organization (WHO).
In the absence of a licensed vaccine to protect against Ebola virus disease (EVD) or a specific drug for treatment in the large Ebola virus outbreak 2013-2016 in Guinea, Liberia and Sierra Leone, potential new Ebola vaccines and therapies were reviewed by the World Health Organization (WHO).